Agenus reports response rate in colon cancer trial
What it means
- What to watch: Policy moves the whole healthcare aisle; trial data moves one company. Knowing which kind of story this is helps.
- How the stock is trading: $AGEN -2.76% in the latest session.
- Timing: It landed over the weekend, while the market was off the clock: the change beside it is Friday's, and Monday is the first session that could react. Market holidays are not detected.
Where the stock stands
$AGEN last changed hands at $6.33, -2.76% on the session, 39% below its 52-week high of $10.31 and 134% above its low of $2.71 — around the middle of the range. Over the year it has ranged 280% from low to high: a very wide band — this one has spent the year on a roller coaster, and big swings are business as usual. These are latest-session quotes, not live prices — the live tape is on the $AGEN page.
How much coverage it is getting
In the last 30 days Wook has filed 2 stories about $AGEN — 2 of them this week. At its 30-day pace you would expect less than one a week, so this week is running well ahead of normal — something has the newsroom's attention. Across those stories 0 read bullish, 2 neutral and 0 bearish — mostly headline writers keeping a straight face. This one reads neutral, so it sits squarely with the crowd. This is the only one from Seeking Alpha; the rest came from other outlets. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
Coming up
$AGEN earnings in 15 days. These were on the calendar before this story and are not caused by it.
What to watch next
The $AGEN page has the full chart, the filings and the valuation model behind every figure here. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. And Wook AI, up top, will happily do the math — how far $AGEN sits from its high, or how this week's coverage stacks up.
How this analysis was made
Seeking Alpha published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $AGEN. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.